FTO and acute myeloid leukemia: To better understand the underlying mechanisms on how FTO degrader inhibits AML cell proliferation, we performed RNA sequencing (RNA-seq) and m6A-RNA immunoprecipitation sequencing (m6A-RIP-seq) in dimethyl sulfoxide (DMSO)– or FP54-treated MOLM-13 (Fig. 3A).